Conferences
Convening the Regenerative Medicine Community
Translational Regenerative Medicine
April 6-8, 2010
Twin City Quarter
Winston-Salem, NC
Call For Abstracts
Download the Call for Abstracts: Deadline for Submission January 29, 2010 ms-word pdf
Drivers and Strategies for Healthcare Innovation and Personalized Medicine
April 6, 2010: Media Academy and Opening Reception
April 7, 2010: Advancing the Field
April 8, 2010: Advancing Business Models and Best Practices
Featuring Leaders from:
Acorda Therapeutics
Advanced BioHealing
Advanced Cell & Gene Therapy
Advanced Cell Technology
Aldagen
America Stem Cell, Inc.
ATCC
Athersys
GE Healthcare
Histogen
iPierian
Integra
Life Technologies
Novartis Institutes for Biomedical Research
Organogenesis
Pfizer
Stem Cell Therapeutics Corp.
Stratatech
Tengion
Transgeneron
DeNovo Ventures
Excel Venture Management
InterSouth Partners
Livingston Securities
Proteus Ventures
Quaker BioVentures
Safeguard Scientifics
Juvenile Diabetes Research Foundation
Fast Forward
Agency for Science, Technology and Research (A*STAR)
Armed Forces Institute for Regenerative Medicine (AFIRM)
California Institute for Regenerative Medicine (CIRM)
Harvard Stem Cell Institute
Johns Hopkins University
Northwestern University, Feinberg Neuroscience Institute
Northwestern University School of Medicine
Shanghai Jiao Tong University, School of Medicine and Shanghai 9th People’s Hospital
Tokyo Women's Medical University, Institute of Advanced Biomedical Engineering and Science
University of Kansas, Institute for Advancing Innovation
University of Miami Miller School of Medicine, Institute for Diabetes Research
University of Washington
Virginia Tech
Wake Forest Institute for Regenerative Medicine (WFIRM)
U.S. Army Medical Research
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (CBER)
National Institute for the Control of Pharmaceutical and Biological Products (SFDA)
The Aspen Institute
Center for Health Transformation
Genetics Policy Institute
Greenleaf Health, LLC
Kauffman Foundation
Hogan & Hartson
Holland & Knight
Adjuvant Global Advisors
Cell Therapy Group
About the Forum
The Translational Regenerative Medicine Forum is the premiere event for leaders in regenerative medicine translation, representing academic research, clinical, healthcare policy, regulatory, reimbursement, investment and biotechnology industry interests. In order to facilitate business development opportunities and investment, the meeting will include a venture forum featuring 15 regenerative medicine companies
Corporate Registration
$850.00 through March 15, 2010
$975.00 after March 15, 2010 or Onsite
Academic/Not-for-Profit Government Registration
$495.00
For more information about the inaugural 2010 conference, please contact Jon Obermeyer at the Regenerative Medicine Foundation: 336.509.3080 or jon@regenerativemedicinefoundation.org
2010 Program Committee
Tim Bertram, Tengion
Lee Buckler, Cell Therapy Group
Scott R. Burger, MD, Advanced Cell & Gene Therapy
Jeff Karan, Proteus Ventures
Lesa Mitchell, Kauffman Foundation
Michelle McMurry, The Aspen Institute
Morrie Ruffin, Adjuvant Global Advisors
Steve Binion, Regulatory Affairs, BD
David F. Williams, D.Sc., FREng., Wake Forest Institute for Regenerative Medicine
James Yoo, M.D., Ph.D., Wake Forest Institute for Regenerative Medicine
Promotional Partners
Tissue Engineering and Regenerative Medicine International Society (TERMIS) www.termis.org
Genetics Policy Institute www.genpol.org
